Nov 15, 2019
FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
Oct 28, 2019
CARsgen Announces Investigational CAR-T Therapy CT053 Granted RMAT Designation by the U.S. FDA for R/R Multiple Myeloma
Oct 28, 2019
Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain
Oct 22, 2019
BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
Oct 01, 2019
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain
Sep 17, 2019
FDA takes first action under new international collaboration with Australia and Canada designed to provide a framework for concurrent review of cancer therapies, approving treatment for patients with endometrial carcinoma
Aug 13, 2019
Windtree Announces FDA Fast Track Designation for Istaroxime
Aug 02, 2019
FDA approves first therapy for rare joint tumor
Jul 03, 2019
FDA approves new treatment for refractory multiple myeloma
Jun 05, 2019
Sierra Announces Momelotinib Granted FDA Fast Track Designation
May 24, 2019
Users Rule Under Huobi's New FastTrack Listing Model
Apr 18, 2019
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin
Mar 21, 2019
Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
Feb 19, 2019
Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA for the Treatment of TK2 Deficiency
Nov 26, 2018
FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
Sep 28, 2018
FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation
Sep 27, 2018
HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Primary Sclerosing Cholangitis
Sep 13, 2018
FDA approves new kind of treatment for hairy cell leukemia
Aug 27, 2018
Cantex Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CX-01 For The Treatment Of Patients Over Age 60 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Aug 23, 2018
Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy